{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:09:29Z","timestamp":1791659369659,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates (ADCs) have transformed breast-cancer therapeutics by combining targeted antibody delivery with potent cytotoxic payloads. With the expanding use of trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) across HER2-positive, HER2-low, and hormone-receptor\u2013positive disease, management of treatment-related toxicities has become a critical determinant of outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize clinical-trial, post-marketing, and real-world data to create a unified, organ-system\u2013based framework for anticipating, preventing, and managing toxicities associated with these ADCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted narrative review was conducted using PubMed, Embase, and ClinicalTrials.gov (January 2019 \u2013 December 2025). Phase II\/III trials, meta-analyses, pharmacovigilance studies, and expert-consensus guidelines on ADC safety in breast cancer were included. Pre-clinical and non-breast ADC studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparative synthesis demonstrates overlapping but distinct toxicity signatures driven by payload, linker stability, and antigen expression. Integrating these findings, we propose practical algorithms for managing pulmonary, gastrointestinal, hematologic, ocular, and mucosal adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review consolidates evidence into a clinician-oriented reference for ADC toxicity management, emphasizing multidisciplinary coordination, early recognition, and system-specific mitigation strategies to enhance treatment safety and adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1755574","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:56:43Z","timestamp":1780030603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of toxicities from antibody \u2013 drug conjugates in breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Ajay","family":"Gogia","sequence":"first","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4137\/cmo.s6460","article-title":"Trastuzumab for HER2-positive metastatic breast cancer: Clinical and economic considerations","volume":"6","author":"Jeyakumar","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177202","article-title":"Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment","volume":"988","author":"Xu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","author":"Loibl","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.253","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.mcr-19-0582","article-title":"Antibody-drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: First approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B19","unstructured":"ENHERTU PI"},{"key":"B20","unstructured":"TRODELVY PI"},{"key":"B21","unstructured":"DATROWAY PI"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795","article-title":"Treatment-related adverse events associated with HER2-targeted antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"55","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103208","article-title":"186P exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2+ or HER2-low unresectable and\/or metastatic breast cancer (mBC) in DESTINY-Breast trials","volume":"9","author":"Park","year":"2024","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"B30","article-title":"ENHERTU (fam-trastuzumab deruxtecan-nxki) prescribing information","year":"2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103309","DOI":"10.1016\/j.eclinm.2025.103309","article-title":"Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial","volume":"85","author":"P\u00e9rez-Garc\u00eda","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B32","article-title":"TRODELVY (sacituzumab govitecan-hziy) prescribing information","year":"2025"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.3159","article-title":"Multicenter interspecialty consensus on experimental oncology drug-related ocular adverse event reporting","author":"Pasricha","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"B34","article-title":"DATROWAY (datopotamab deruxtecan-dlnk) prescribing information","year":"2025"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103326","article-title":"267MO pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease\/pneumonitis (ILD)","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/op.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/op.23.00097","article-title":"Detecting and managing T-DXd-related interstitial lung disease: The five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: A systematic review and meta-analysis","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2005.08.009","article-title":"Chemotherapeutic drugs in pregnancy","volume":"32","author":"Leslie","year":"2005","journal-title":"Obstet Gynecol Clin North Am"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/jm800719t","article-title":"Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy","volume":"51","author":"Moon","year":"2008","journal-title":"J Med Chem"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","article-title":"Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial","volume":"42","author":"Picte","year":"2024","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mrgentox.2006.01.003","article-title":"Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster","volume":"604","author":"Sortibran","year":"2006","journal-title":"Mutat Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/17.2.141","article-title":"Comparison of camptothecin derivatives presently in clinical trials: Genotoxic potency and mitotic recombination","volume":"17","author":"Cunha","year":"2002","journal-title":"Mutagenesis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0456","article-title":"Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.esmoop.2024.103479","article-title":"LBA2 datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable\/metastatic HR+\/HER2- breast cancer (BC): additional safety analysis from TROPION-Breast01","volume":"9","author":"Jhaveri","year":"2024","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz225","article-title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","volume":"28","author":"Shekarian","year":"2017","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: An observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: Potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0722","article-title":"Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ Malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1755574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:56:48Z","timestamp":1780030608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1755574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1755574"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1755574","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1755574"}}